DIA423.85+7.52 1.81%
SPX5,921.54+118.72 2.05%
IXIC19,199.16+461.96 2.47%

先瑞達醫療-B(06669):AcoStream™二代獲國家藥監局批准註冊

Zhitongcaijing·04/06/2023 10:26:10
Listen to the news

智通財經APP訊,先瑞達醫療-B(06669)發佈公告,於2023年4月4日,公司收到中國國家藥品監督管理局對AcoStream™二代的註冊批准。AcoStream™二代是用於去除外周血管系統中血栓的產品。集團改進了產品的設計從而進一步提升了治療效果和操作便捷度。公司將在中國市場適時開展市場營銷活動。

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.